0001503274 false 0001503274 2023-01-06 2023-01-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549





Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): January 6, 2023



(Exact name of registrant as specified in its charter)


Delaware 001-38319 20-8957988
(State or other jurisdiction
of incorporation)
(Commission File Number) (IRS Employer
Identification No.)


900 Middlesex Turnpike
Billerica, MA
(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (617) 301-9400


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class  Trading symbol(s)  Name of each exchange on which
Common Stock, $0.001 par value per share  QTRX  The Nasdaq Global Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 


Emerging Growth Company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨





Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On January 6, 2023, the board of directors (the “Board”) of Quanterix Corporation (the “Company”) appointed Brian J. Blaser to serve on the Board effective immediately. Mr. Blaser will serve as a Class III director with a term that will expire at the Company’s 2023 annual meeting of stockholders.


There is no arrangement or understanding between Mr. Blaser and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between Mr. Blaser and any of the Company’s other directors or executive officers. Mr. Blaser does not have a material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K.


In accordance with the Company’s amended and restated non-employee director compensation policy (the “Policy”), Mr. Blaser received an equity award valued at $400,000 comprised of (i) 60% non-qualified stock options to purchase the Company’s common stock at an exercise price equal to the closing price of the common stock on January 6, 2023 and (ii) 40% RSUs. The options vest over three years from the date of grant, with one-third vesting on the first anniversary and the remainder vesting over the following two years in 24 successive equal monthly installments. The RSUs vest over a three-year period, with one-third vesting on each of the first, second, and third anniversaries of the grant date. Mr. Blaser will also receive annual compensation and annual equity awards as further provided in the Policy. A description of the Policy is available in the Company’s proxy statement filed with the Securities and Exchange Commission on April 29, 2022 (File No. 001-38319) under the heading “Executive Officer and Director Compensation – Director Compensation – Non-Employee Director Compensation Policy.”


A copy of the press release dated January 9, 2023 announcing the appointment of Mr. Blaser is filed as Exhibit 99.1 hereto and is incorporated by reference herein.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


99.1   Press Release dated January 9, 2023.
104   Cover Page Interactive Data File (embedded within the inline XBRL document)





Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


  By: /s/ Mike Doyle
    Mike Doyle
    Chief Financial Officer


Date: January 9, 2023




Exhibit 99.1


Quanterix Announces Appointment of Brian Blaser to Board of Directors


Billerica, Mass. – Jan. 9, 2023 Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it has appointed Brian Blaser to its Board of Directors effective as of January 6, 2023.


Mr. Blaser brings over 25 years of senior leadership experience in the in-vitro diagnostics industry, including 15 years at Abbott Laboratories where he was responsible for the company’s global diagnostics organization, including its core laboratory, point of care, rapid diagnostics, and molecular diagnostics businesses. While at Abbott, he was responsible for the launch of the Alinity family of laboratory instruments and oversaw the acquisition of Alere that made Abbott the global leader in point-of-care and rapid diagnostic testing. Most recently, Mr. Blaser served as a Senior Advisor to McKinsey and is currently a Director and Chair of the Audit Committee for Rockley Photonics. Over his career, he has held key leadership positions in operations, finance, and engineering with the Ortho Clinical Diagnostics division of Johnson & Johnson, Eastman Kodak, and General Motors.


“Throughout his career, Brian has defined and implemented transformational strategies to accelerate growth, increase scale, and dramatically improve profitability,” said Masoud Toloue, CEO at Quanterix. “His history of strategic leadership and breadth of operational excellence further strengthens the collective expertise of our board, and we look forward to leveraging his deep knowledge and experience across clinical and diagnostics settings.”


“I have always been passionate about building diverse teams that thrive on a foundation of exceptional performance, teamwork, and accountability, and I am excited to bring this passion to Quanterix’s Board of Directors at a time when the company is poised for continued success,” said Blaser. “Having led teams that have implemented transformative business strategies to accelerate growth and expansion, I look forward to guiding the company’s mission-critical work as it transitions deeper into its diagnostics strategy.”


Mr. Blaser received his Master of Business Administration from the Rochester Institute of Technology and his Bachelor of Science in Mechanical Engineering Technology from the University of Dayton. He currently serves as Chair of the University of Dayton School of Engineering Advisory Council and as Chairman of the Board of Trustees for Cristo-Rey St. Martin College Prep. Mr. Blaser has also served on the Board of Directors for AdvaMed.


“Brian’s proven experience and significant achievements in diagnostics will be invaluable additions to the company as it continues to expand its commercial potential,” said Martin Madaus, Ph.D., Chairman of Quanterix’s Board of Directors. “On behalf of the entire board, I am delighted that Brian has decided to step into this new role.”


To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix’s Simoa® technology, visit: https://www.quanterix.com/technology.





About Quanterix


From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,000 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.


Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.


Media Contact:

Maya Nimnicht, PAN Communications

(510) 334-6273



Investor Relations Contact:

Amy Achorn, Quanterix

(978) 488-1854